Doxy - Hem capsules 500mg, No. 90

Vascular lesions with increased fragility and capillary permeability (diabetic retinopathy and nephropathy) and other microangiopathies associated with various cardiovascular and metabolic diseases.
Venous insufficiency of varying severity and its consequences (pre-varicose state with symptoms of tissue edema, pain, paresthesia, congestive dermatosis; superficial phlebitis, varicose veins, trophic ulcers).

Inside, without chewing, during meals.

Prescribe 500 mg 3 times a day for 2-3 weeks, then the dose is reduced to 500 mg once a day.

In the treatment of retinopathy and microangiopathy, 500 mg is prescribed 3 times a day for 4-6 months, then the daily dose is reduced to 500 mg once a day.

1 capsule contains the
active substance: calcium dobesilate (in the form of calcium dobesilate monohydrate 521, 51 mg) - 500.0 mg,
excipients: corn starch, magnesium stearate; capsule shell: titanium dioxide E 171, iron dye yellow oxide E172, iron dye black oxide E172, indigo carmine dye (indigotin I) E132, gelatin.

Hypersensitivity to the drug, gastric ulcer and 12 duodenal ulcer (in the acute stage), bleeding from the gastrointestinal tract, kidney and liver diseases, hemorrhages caused by anticoagulants; pregnancy (I trimester), children's age (up to 13 years).

Trade name of the drug: Doxy-ChemЃ

International non-proprietary name:

Calcium dobesylate

Dosage form:

capsules

Composition
1 capsule contains the
active substance: calcium dobesilate (in the form of calcium dobesilate monohydrate 521, 51 mg) - 500.0 mg,
excipients: corn starch, magnesium stearate; capsule shell: titanium dioxide E 171, iron dye yellow oxide E172, iron dye black oxide E172, indigo carmine dye (indigotin I) E132, gelatin.

Description
Hard gelatin capsule No. 1, the body of the capsule is opaque yellow, the cap is dark green.
Capsule content: white to yellowish-white powder. The presence of conglomerates is allowed, which turn into a free-flowing powder when lightly pressing a glass rod.

Pharmacotherapeutic group:

angioprotective agent

ATX code: [C05BX01].

Pharmacological properties
Angioprotector, reduces increased vascular permeability, increases the resistance of capillary walls, improves microcirculation and drainage function of lymphatic vessels, moderately reduces platelet aggregation and blood viscosity, increases the elasticity of the erythrocyte membrane. The action is associated to a certain extent with an increase in the activity of plasma kinins.
The drug is slowly absorbed in the gastrointestinal tract. The maximum concentration in the blood after oral administration is observed after 5-6 hours. Plasma protein binding is 20-25%, the half-life is 5 hours. It practically does not penetrate the blood-brain barrier. It is excreted mainly by the kidneys within 24 hours and by the intestines.

Indications for use
Vascular lesions with increased fragility and capillary permeability (diabetic retinopathy and nephropathy) and other microangiopathies associated with various cardiovascular and metabolic diseases.
Venous insufficiency of varying severity and its consequences (pre-varicose state with symptoms of tissue edema, pain, paresthesia, congestive dermatosis; superficial phlebitis, varicose veins, trophic ulcers).

Contraindications
Hypersensitivity to the drug, gastric ulcer and 12 duodenal ulcer (in the acute stage), bleeding from the gastrointestinal tract, kidney and liver diseases, hemorrhages caused by anticoagulants; pregnancy (I trimester), children's age (up to 13 years).

Method of administration and dosage
Inside, without chewing, during meals.

Prescribe 500 mg 3 times a day for 2-3 weeks, then the dose is reduced to 500 mg once a day.

In the treatment of retinopathy and microangiopathy, 500 mg is prescribed 3 times a day for 4-6 months, then the daily dose is reduced to 500 mg once a day.

Side effects
Disorders from the gastrointestinal tract (nausea, vomiting, diarrhea, gastralgia), allergic dermatosis, increased activity of hepatic transaminases, febrile reactions, headache, dizziness.

Overdose
No cases of overdose have been reported.

Interaction with other drugs
Enhances the effect of indirect anticoagulants, heparin, GCS, hypoglycemic effect of sulfonylurea derivatives. Increases the antiplatelet activity of ticlopidine. It is not recommended to combine with Li + drugs and methotrexate.

Special instructions:

The drug can be administered prophylactically.
The dose should be reduced in cases of severe renal failure requiring dialysis.

Release form:

Capsules 500 mg. 10 capsules in a PVC / A1 blister. 3 blisters with instructions for use in a cardboard box.

Storage conditions:

List B.
At a temperature of 15 to 25 ? C in a dry place.
Keep out of the reach of children.

Shelf life:

5 years. Do not use after the expiration date printed on the package.

Terms of dispensing from pharmacies:

On prescription.